CA-LASERFICHE
5.7.2022 18:24:07 CEST | Business Wire | Press release
Laserfiche — the leading SaaS provider of intelligent content management and business process automation — has been named a Leader in the Nucleus Research Technology Value Matrix for Content Services and Collaboration for its deep industry expertise, ease of use and process automation features. Out of the 15 vendors evaluated, Laserfiche ranked highest for both functionality and usability.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220705005673/en/
“Over the past three years, digitization has become a core component of business survival across organizational sizes and industry types,” the report states. “Now, the ongoing prevalence of fully remote and hybrid work structures has highlighted the importance of having modern solutions for content management and collaboration in place to ensure maintained efficiency and end-user productivity.”
With SaaS, self-hosted or hybrid deployment models, the Laserfiche platform enables flexible and scalable solutions for digital transformation through business process automation, analytics and content management capabilities. This year, Laserfiche launched the Laserfiche Solution Marketplace, a publicly-accessible collection of industry- and department-specific solution templates that enable rapid development and deployment of electronic forms, automated workflows and integrations. Laserfiche provides an easy-to-use process automation canvas and a toolbox with more than 150 no-code activities for integrations and backend processing tasks, including RPA bots, document capture, automated document creation and decision tables.
“Laserfiche ranks highest in the Leaders quadrant for its heavy focus on content-centric business process automation and its intuitive no-code and low-code tools,” said Evelyn McMullen, research manager at Nucleus Research. “The platform’s ease of use and robust capabilities enable customers to automate thousands of processes across their organizations, with the ability to design solutions to meet their unique organizational or regulatory needs.”
“We’re honored to be a leader that is ranked the highest in both usability and functionality based on industry research and customer feedback,” said Laserfiche SVP of Corporate Strategy and CIO Thomas Phelps. “Laserfiche is passionate about collaborating with customers — especially business technologists who create no-code solutions — to provide products that drive business innovation. Content-centric process automation is critical to a digital workplace that engages employees in delivering outstanding customer experiences.”
“As a world-class administrator of health and pension benefits, MPI aims to set the bar for quality of service,” said Joel Manfredo, CIO at Motion Picture Industry Pension & Health Plans (MPI). “Laserfiche’s usability, robust functionality and innovative road map support MPI’s strategic vision for technology, which prioritizes the use of automated solutions that create the best possible experience for our participants and employees.”
To learn more about Laserfiche’s position in the Content Services and Collaboration market, download the report here .
About Laserfiche
Laserfiche is the leading SaaS provider of intelligent content management and business process automation. Through powerful workflows, electronic forms, document management and analytics, the Laserfiche® platform accelerates how business gets done, enabling leaders to focus on growth across the enterprise.
Laserfiche pioneered the paperless office with enterprise content management. Today, Laserfiche’s cloud-first development approach incorporates innovations in machine learning and AI to enable organizations in more than 80 countries to transform into digital businesses. Customers in every industry — including government, education, financial services, healthcare and manufacturing — use Laserfiche to boost productivity, scale their business and deliver digital-first customer experiences.
Laserfiche employees in offices around the world are committed to the company’s vision of empowering customers and inspiring people to reimagine how technology can transform lives.
Connect with Laserfiche:
Laserfiche Blog | Twitter | LinkedIn | Facebook
View source version on businesswire.com: https://www.businesswire.com/news/home/20220705005673/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom